Skip to main content
Premium Trial:

Request an Annual Quote

Cellartis Working with Pfizer on Predictive NCE Screening

NEW YORK (GenomeWeb News) – Pfizer has tapped Cellartis to help it develop an in vitro screening model for predicting toxicity of new chemical entities in humans.
 
Cellartis said Tuesday that the collaboration gives Pfizer access to its human Embryonic Stem cell technology to develop the screening system, for which Cellartis will receive an upfront fee and research funding, and it will hold the rights to sub-license, use, and sell the toxicity screening model.
 
Current methods for identifying human teratogens include mouse, rat, or rabbit data, the company said, but the novel ES cell-based system could make it possible to develop toxicity data at the pre-clinical, in vitro phase.
 
Under the agreement, Cellartis will develop the human ES cell model system and will conduct validation testing on compounds, and Pfizer will provide expertise and capabilities to help design a developmental toxicity prediction model.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.